H
Huw Roddie
Researcher at Western General Hospital
Publications - 28
Citations - 1713
Huw Roddie is an academic researcher from Western General Hospital. The author has contributed to research in topics: Multiple myeloma & Zoledronic acid. The author has an hindex of 16, co-authored 26 publications receiving 1580 citations. Previous affiliations of Huw Roddie include University of Edinburgh.
Papers
More filters
Journal ArticleDOI
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J. Morgan,Faith E. Davies,Walter M Gregory,Kim Cocks,Sue E. Bell,Alex J Szubert,Nuria Navarro-Coy,Mark T. Drayson,Roger G. Owen,Sylvia Feyler,A John Ashcroft,Fiona M. Ross,Jennifer Byrne,Huw Roddie,Claudius Rudin,Gordon Cook,Graham Jackson,J. Anthony Child +17 more
TL;DR: These findings support immediate treatment with zoledronic acid in patients with newly diagnosed multiple myeloma, not only for prevention of skeletal-related events, but also for potential antimyeloma benefits.
Journal ArticleDOI
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.
Gareth J. Morgan,Walter M Gregory,Faith E. Davies,Sue E. Bell,AJ Szubert,Julia Brown,Nuria Navarro Coy,Gordon Cook,Nigel H. Russell,Claudius Rudin,Huw Roddie,Mark T. Drayson,Roger G. Owen,Fiona M. Ross,Graham Jackson,J. Anthony Child +15 more
TL;DR: Overview analysis demonstrated that thalidomide maintenance was associated with a significant late OS benefit, and iFISH testing is important in assessing the clinical impact of maintenance therapy.
Journal ArticleDOI
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
Gareth J. Morgan,Faith E. Davies,Walter M Gregory,Nigel H. Russell,Sue E. Bell,AJ Szubert,Nuria Navarro Coy,Gordon Cook,Sylvia Feyler,Jennifer Byrne,Huw Roddie,Claudius Rudin,Mark T. Drayson,Roger G. Owen,Fiona M. Ross,Graham Jackson,J. Anthony Child +16 more
TL;DR: In elderly patients with newly diagnosed multiple myeloma (median age, 73 years), CTDa produced higher response rates than MP but was not associated with improved survival outcomes, which highlights the importance of cytogenetic profiling at diagnosis and effective management of adverse events.
Journal ArticleDOI
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
Gareth J. Morgan,J. Anthony Child,Walter M Gregory,Alex J Szubert,Kim Cocks,Sue E. Bell,Nuria Navarro-Coy,Mark T. Drayson,Roger G. Owen,Sylvia Feyler,A John Ashcroft,Fiona M. Ross,Jennifer Byrne,Huw Roddie,Claudius Rudin,Gordon Cook,Graham Jackson,Ping Wu,Faith E. Davies +18 more
TL;DR: The results of this study support the early use of zoledronic acid rather than clodronic acid in patients with newly diagnosed multiple myeloma for the prevention of skeletal-related events, irrespective of bone disease status at baseline.
Journal ArticleDOI
A multi‐centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion
Miguel Lozano,Folke Knutson,R. Tardivel,Joan Cid,Rosa Maria Maymó,Helena Löf,Huw Roddie,Jane Pelly,Anthony Docherty,Claire D. Sherman,Lily Lin,Meisa Propst,Lawrence Corash,Chris Prowse Prowse +13 more
TL;DR: Storage of A‐PCs for 6–7’d had no impact on platelet efficacy and time to next PC transfusion after study PC was not significantly different between groups.